1. Home
  2. NUVB vs GOOS Comparison

NUVB vs GOOS Comparison

Compare NUVB & GOOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NUVB
  • GOOS
  • Stock Information
  • Founded
  • NUVB 2018
  • GOOS 1957
  • Country
  • NUVB United States
  • GOOS Canada
  • Employees
  • NUVB N/A
  • GOOS N/A
  • Industry
  • NUVB Biotechnology: Pharmaceutical Preparations
  • GOOS
  • Sector
  • NUVB Health Care
  • GOOS
  • Exchange
  • NUVB Nasdaq
  • GOOS Nasdaq
  • Market Cap
  • NUVB 1.1B
  • GOOS 1.3B
  • IPO Year
  • NUVB N/A
  • GOOS 2017
  • Fundamental
  • Price
  • NUVB $5.04
  • GOOS $13.98
  • Analyst Decision
  • NUVB Strong Buy
  • GOOS Hold
  • Analyst Count
  • NUVB 7
  • GOOS 5
  • Target Price
  • NUVB $8.43
  • GOOS $12.40
  • AVG Volume (30 Days)
  • NUVB 8.2M
  • GOOS 553.3K
  • Earning Date
  • NUVB 11-03-2025
  • GOOS 11-06-2025
  • Dividend Yield
  • NUVB N/A
  • GOOS N/A
  • EPS Growth
  • NUVB N/A
  • GOOS N/A
  • EPS
  • NUVB N/A
  • GOOS 0.35
  • Revenue
  • NUVB $14,355,000.00
  • GOOS $1,001,779,346.00
  • Revenue This Year
  • NUVB $291.13
  • GOOS $8.35
  • Revenue Next Year
  • NUVB $332.00
  • GOOS $6.02
  • P/E Ratio
  • NUVB N/A
  • GOOS $39.45
  • Revenue Growth
  • NUVB 900.35
  • GOOS 2.32
  • 52 Week Low
  • NUVB $1.54
  • GOOS $6.73
  • 52 Week High
  • NUVB $5.12
  • GOOS $15.43
  • Technical
  • Relative Strength Index (RSI)
  • NUVB 76.90
  • GOOS 60.15
  • Support Level
  • NUVB $3.36
  • GOOS $13.02
  • Resistance Level
  • NUVB $3.84
  • GOOS $13.57
  • Average True Range (ATR)
  • NUVB 0.29
  • GOOS 0.48
  • MACD
  • NUVB 0.11
  • GOOS 0.01
  • Stochastic Oscillator
  • NUVB 95.45
  • GOOS 90.98

About NUVB Nuvation Bio Inc.

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.

About GOOS Canada Goose Holdings Inc. Subordinate Voting Shares

Canada Goose Holdings Inc is a Canada-based company that designs, manufactures, distributes, and retails premium outerwear for men, women, and children. It operates business through three segments namely, Wholesale and Direct to Consumer (DTC), Other. The DTC segment, which is the key revenue driver, comprises sales through country-specific e-commerce platforms and its company-owned retail stores located in luxury shopping locations. The Wholesale segment comprises sales made to a mix of retailers and international distributors, who are partners that have exclusive rights to an entire market, and travel retail locations. Geographically, it has a presence in Canada, the United States, North America, Greater China, Asia, and Europe, the Middle East, and Africa.

Share on Social Networks: